ReviewFrontiers in immunology2026
Efferocytosis failure in chronic rhinosinusitis with nasal polyps: receptor-level mechanisms of unresolved type 2 inflammation.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a prototypical type 2 airway disease in which tissue eosinophilia persists. That persistence is conventionally attributed to excess recruitment and to slowed apoptosis. Both explanations concern arrival and survival, and neither specifies what becomes of an eosinophil once it has died. That step is efferocytosis, the receptor-guided ingestion of apoptotic cells by macrophages, which differs from microbial phagocytosis in its ligands, its signaling output and its metabolic consequences. We establish this distinction first, because it decides which published datasets qualify as evidence and which do not. We then grade the surviving evidence and propose a cascade-anchored model in which failure is localized to three candidate lesions in the polyp macrophage: loss of an interleukin-10-dependent, MerTK-competent subset; a receptor repertoire skewed toward AXL and TIM-4 in which expression is uncoupled from productive ingestion; and an execution block at the phosphoinositide and Rac1 module. This model assigns the macrophage subsets reported in CRSwNP, including IL-10-deficient, ALOX15-positive, TIM-4-positive, TIPE2-positive, HMOX1-high and INPP4A-deficient populations, to defined steps rather than to a
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.